Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study);Hábitos de prescripción de rivastigmina en solución en pacientes con demencia de tipo Alzheimer en España (estudio RIVASOL)

Revista de Neurologia

Volumn 44, Issue 12, 2007, Pages 705-710

  González Gutiérrez, José Luis ^a   Gobartt, A L ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Novartis Farmacéutica SA   (Switzerland)

Author keywords

Alzheimer; Demand for health care; Dosage; Observational study; Rivastigmine solution; Safety

Indexed keywords

RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DESCRIPTIVE RESEARCH; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; PRESCRIPTION; RETROSPECTIVE STUDY; SPAIN; TREATMENT DURATION; CLINICAL PRACTICE; NEUROPSYCHOLOGICAL TEST;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; HUMANS; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SPAIN;

EID: 34948841027     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4412.2007043     Document Type: Article

References (30)

1. Mayor S. NICE recommends drugs for moderate Alzheimer's disease. BMJ 2006; 332: 195.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 25: CD005593.
3. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, Van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ 2005; 331: 321-7.
4. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. A meta-analysis. JAMA 2003; 289: 210.
5. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drug Aging 2004; 21: 453-78.
6. Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006; 10: 1-160.
7. Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241-5.
8. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54: 465-73.
9. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA 1998; 280: 1777-82.
10. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994; 271: 985-91.
11. Arrieta JL, Artalejo FR. Methodology, results and quality of clinical trials of tacrine in the treatment of Alzheimer's disease: a systematic review of the literature. Age Ageing 1998; 27: 161-79.
12. Soares JC, Gershon S. THA -historical aspects, review of pharmacological properties and therapeutic effects. Dementia 1995; 6: 225-34.
13. Davis KL, Powchik P. Tacrine. Lancet 1995; 345: 625-30. 14. Allain H, Bentué-Ferrer D. The anti-dementia drugs: myth, hype or reality? Clin Neuropharmacol 2006; 29: 10-4.
14. Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17: 159-65.
15. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002; 47: 64-70.
16. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, et al. Kinetic and structural studies on the interaction of cholinesterase with the anti-Alzheimer drug rivastigmine. Biochemistry 2002; 41: 3555-64.
17. Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005; 102: 17213-8.
18. Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 2006; 22: 483-94.
19. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 25: 1317-27.
20. O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA, et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 2003; 13: 231-9.
21. Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodinamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 2000; 15: 242-7.
22. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000; 4: CD001191.
23. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8.
24. Farlow MR, Lilly ML, ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr 2005; 5: 3.
25. Forchetti CM. Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies. Prim Care Companion. J Clin Psychiatry 2005; 7: 155-61.
26. Morris JC. Dementia update 2005. Alzheimer Dis Assoc Disord 2005; 19: 100-17.
27. Borenstein AR, Copenhaver CI, Mortimer JA. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20: 63-72.
28. Najarian R, Seshadri S, Beiser A, Au R, Wolf PA. Blood pressure, weight loss, and Alzheimer's disease: insights from the Framingham Study. Neurology 2003; 60 (Suppl): S207.
29. Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 2005; 59: 817-22.
30. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006; 60: 110-8.